title: What's new in the migraine attack treatment.
abstract: This short review aims to give a focus on news in the migraine attack treatment and discusses the CGRP receptor antagonists (gepants), the 5-HT1F receptors agonists (ditans), the transcranial magnetic stimulation for the treatment of migraine attack with aura, innovative delivery systems for sumatriptan and the oral inhalation of dihydroergotamine.
authors.affiliation: Département évaluation et traitement de la douleur, pôle neurosciences cliniques, hôpital de Cimiez, CHU de Nice, 4, avenue Reine-Victoria, 06001 Nice, France. lanteri-minet.m@chu-nice.fr
authors.forename: M
authors.initials: M
authors.lastname: Lanteri-Minet
mesh_terms: D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D004087:Dihydroergotamine / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008881:Migraine Disorders / Q000628:therapy*; D059408:Pain Management / Q000379:methods* / Q000639:trends*; D011985:Receptors, Serotonin / Q000378:metabolism; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D018170:Sumatriptan / Q000627:therapeutic use; D050781:Transcranial Magnetic Stimulation; D000096642:Receptor, Serotonin, 5-HT1F
chemical_list: D000700:Analgesics; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D004087:Dihydroergotamine; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; D018170:Sumatriptan; D000096642:Receptor, Serotonin, 5-HT1F